NCT06766435 Evaluation of the Abbott i-STAT TBI Biomarker Test
| NCT ID | NCT06766435 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Traumatic Brain Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 450 participants |
| Start Date | 2025-01-30 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 450 participants in total. It began in 2025-01-30 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
According to the Centers for Disease Control and Prevention, approximately 200,000 hospitalizations occurred in 2020 related to Traumatic Brain Injury (TBI), which does not include many TBIs treated only in emergency departments, urgent care, primary care, or that are not evaluated by a clinician. Head CT is a critical component of care for severe TBI, however in mild TBI there is practice variation with a wider risk to benefit estimation for obtaining head CT imaging. Potential disadvantages of head CT include longer Emergency Department (ED) length of stay (LOS), higher costs, and diagnostic radiation exposure. The i-STAT TBI test is a panel of in vitro diagnostic immunoassays for the quantitative measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in whole blood and a semi-quantitative interpretation of test results derived from these measurements, using the i-STAT Alinity instrument. This biomarker test is cleared for use in adults with mild TBI (Glasgow Coma Scale 13-15) within 24 hours of injury, to aid in determining the need for head CT imaging. Currently, CT head imaging for adults with suspected mild TBI is obtained based on clinicians' usual practice patterns and beliefs about patient expectations. Prior research has demonstrated the blood TBI test may reduce unnecessary CT scans by up to 40%, however the impact on head CT ordering has not yet been studied prospectively. It is important to understand the extent to which a negative TBI biomarker result empowers a clinician to cancel a previously ordered head CT. Given that adult patients with mild TBI often present to EDs, which have access to CT scanners, this is a key setting to assess real-world impact of the i-STAT TBI test on CT head utilization.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Head injury within 24 hours of research blood collection * CT head ordered as part of routine care, not yet completed. * Glasgow Coma Scale (GCS) 13 - 15 Exclusion Criteria: * Unknown whether head injury occurred, and signs of head injury are absent * Previously enrolled in this study in the past 30 days * Prisoner or in police custody or known pregnancy * Suspected current ischemic or hemorrhagic stroke * Suspected open or depressed skull fracture, or signs of skull base fracture * History of multiple sclerosis * Venipuncture not feasible
Contact & Investigator
Shameeke Taylor, MD, MPH, MSCR
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT06766435 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Traumatic Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06766435 currently recruiting?
Yes, NCT06766435 is actively recruiting participants. Contact the research team at Mitali.Pradhan@mountsinai.org for enrollment information.
Where is the NCT06766435 trial being conducted?
This trial is being conducted at New York, United States, New York, United States, New York, United States.
Who is sponsoring the NCT06766435 clinical trial?
NCT06766435 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Shameeke Taylor, MD, MPH, MSCR at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 450 participants.